The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The stability is led by healthy demand in the domestic and emerging markets
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Acute therapies continue to report strong growth compared to chronic ones.
Key takeaways of recent quarter & conference call highlights
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Subscribe To Our Newsletter & Stay Updated
